Table 2.
Comparison of changes in the DCE-MRI parameters between lenalidomide and axitinib between day 3 and day 14.
| DCE-MRI Parameters | Lenalidomide | Axitinib | p-Value | All |
|---|---|---|---|---|
| Number of participants on Day 3 | 41 | 33 | 74 | |
| ΔPeak_D3 (%) | −3.7 (−11.9, 5.2) |
−7.5 (−17.8, 3.6) |
0.265 | −4.3 (−13, 3.8) |
| ΔAUC_D3 (%) | −8 (−18.9, 23.7) |
−25.7 (−53.4, 7.3) |
0.008 * | −12 (−37.4, 1) |
| ΔKtrans_D3 (%) | −0.9 (−40.8, 74.1) |
−30.6 (−64.2, −8.8) |
0.024 * | −21.4 (−49.6, 28.5) |
| Number of participants on Day 14 | 39 | 33 | 72 | |
| ΔPeak_D14 (%) | −2.9 (−11.7, 5.7) |
−11.9 (−22.4, 1.4) |
0.04 * | −4 (−15.9, 4) |
| ΔAUC_D14 (%) | −3.1 (−24.8, 20.2) |
−39.1 (−52.25, −5.9) |
0.002 * | −19.5 (−43.8, 11.5) |
| ΔKtrans_D14 (%) | −7.7 (−45.3, 45.8) |
−47.8 (−71.6, −14.2) |
0.003 * | −22.3 (−57.6, 26.3) |
Note: The data are expressed as the median and interquartile range. * p-value indicates a significant difference.